Journal ArticleDOI
Investigations Into the Drug-Drug Interaction Potential of Tapentadol in Human Liver Microsomes and Fresh Human Hepatocytes
TLDR
The new analgesic tapentadol was evaluated for induction and inhibition of several cytochrome P450 enzymes in vitro, and protein binding was assessed.Abstract:
The new analgesic tapentadol was evaluated for induction and inhibition of several cytochrome P450 enzymes in vitro, and protein binding was assessed. It was concluded that no clinically relevant drug-drug interactions are likely to occur through either mechanism.read more
Citations
More filters
Journal ArticleDOI
Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain.
James E. Wild,Stefan Grond,Brigitte Kuperwasser,Jane S. Gilbert,Bettyanne McCann,Bernd Lange,A. Steup,T. Häufel,Mila Etropolski,Christine Rauschkolb,Robert Lange +10 more
TL;DR: In this article, the authors evaluated the long-term safety and tolerability of tapentadol extended release (ER) in patients with chronic knee or hip osteoarthritis pain or low back pain.
Journal ArticleDOI
Pharmacological treatment of chronic pain – the need for CHANGE
Giustino Varrassi,Gerhard Müller-Schwefe,Joseph V. Pergolizzi,A. Orónska,Bart Morlion,Philippe Mavrocordatos,César Margarit,C. Mangas,Wolfgang Jaksch,Frank Huygen,Beverly Collett,Marco Berti,Dominic Aldington,K. Ahlbeck +13 more
TL;DR: Universal, user-friendly educational tools are required to familiarise physicians with pain mechanisms, sensitisation and multi-mechanistic management, and also to improve communication between physicians and their pain patients, so that realistic expectations of treatment can be established.
Journal ArticleDOI
Mechanistic and functional differentiation of tapentadol and tramadol
Robert B. Raffa,Helmut Buschmann,Thomas Christoph,Gary Eichenbaum,Werner Englberger,Christopher M. Flores,Torsten Hertrampf,Babette Kögel,Klaus Schiene,Wolfgang Strasburger,Rolf Terlinden,Thomas M. Tzschentke +11 more
TL;DR: Tapentadol, a schedule-II controlled substance, is well-suited for pain conditions requiring a strong opioid component—and it has the benefit of greater gastrointestinal tolerability compared to classical strong opioids.
Journal ArticleDOI
Tapentadol in pain management: a μ-opioid receptor agonist and noradrenaline reuptake inhibitor.
TL;DR: Clinical trial evidence in acute and chronic non-cancer pain and neuropathic pain supports an opioid-sparing effect that reduces some of the typical opioid-related adverse effects for tapentadol, which results in improved tolerability and adherence to therapy for both the immediate- and extended-release formulations of tapENTadol.
Journal ArticleDOI
Tapentadol hydrochloride: a centrally acting oral analgesic.
TL;DR: Tapentadol appears to be a well-tolerated and effective analgesic for the treatment of moderate to severe acute pain.